Concepedia

Laleh Kamalian

LK

Statistics

Publications

6

Citations

443

H-Index

6

Active since

2008

Affiliations

University of Liverpool(Current)

Janssen (Belgium)

Janssen (United States)

AstraZeneca (United Kingdom)

Laleh Kamalian is an author at University of Liverpool specializing in mitochondrial toxicity mechanisms, mitochondrial dysfunction, and mitochondrial toxicity.

Publications per year

2008–2019

6

Publications

6

The utility of HepG2 cells to identify direct mitochondrial dysfunction in the absence of cell death

Laleh Kamalian, Amy E. Chadwick, Mark Bayliss et al. · Toxicology in Vitro · 2015 · 154 citations · Full text

, , +17

Mechanistic evaluation of primary human hepatocyte culture using global proteomic analysis reveals a selective dedifferentiation profile

James A. Heslop, Cliff Rowe, Joanne Walsh et al. · Archives of Toxicology · 2016 · 141 citations · Full text

, , +12

Increased Expression of Id Family Proteins in Small Cell Lung Cancer and its Prognostic Significance

Laleh Kamalian, John R. Gosney, Shiva S. Forootan et al. · Clinical Cancer Research · 2008 · 55 citations · Full text

, , +16

The utility of HepaRG cells for bioenergetic investigation and detection of drug-induced mitochondrial toxicity

Laleh Kamalian, Oisin Douglas, Carol Jolly et al. · Toxicology in Vitro · 2018 · 42 citations · Full text

, , +17

Identification of the Additional Mitochondrial Liabilities of 2-Hydroxyflutamide When Compared With its Parent Compound, Flutamide in HepG2 Cells

Amy Ball, Laleh Kamalian, Ana Alfirevic et al. · Toxicological Sciences · 2016 · 29 citations · Full text

, , +17

1–5 of 6